01801 INNOVENT BIO
- 40.250
- +1.100+2.81%
INNOVENT BIO News
Goldman Sachs: Maintaining the Xiaomi Group-W (01810) “Buy” Rating Target Price of HK$20
Goldman Sachs believes that the Xiaomi Group's electric vehicle revenue and gross profit forecast has room for further improvement.
Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 6%, demand for weight loss products surged, and the company's product, Maxidopeptide, has submitted a listing application for weight loss indications
Cinda Biotech (01801) rose more than 6%. As of press release, it rose 6.22% to HK$38.4, with a turnover of HK$299 million.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Cinda Biotech (01801) rose more than 5% in the afternoon, and the cholangiocarcinoma treatment drug Dabertan was approved for listing in Macau, China
Cinda Biotech (01801) rose more than 5% in the afternoon. As of press release, it was up 5.15% to HK$35.7, with a turnover of HK$131 million.
More contests are coming! Global Data: 13 new weight loss drugs are expected to be launched by 2029
Pharmacists are preparing to launch around 13 new weight loss treatments in the US within the next five years due to a surge in demand for weight loss products, according to a new report from global data analysis and consulting firm Global Data.
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Press Release: Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Nageatte Ibrahim
Hong Kong Stock Concept Tracking | Novo Nordisk's new weight loss drug clinical approval industry in China will usher in a period of breakthrough results (with concept stocks)
On April 10, the official website of the Drug Evaluation Center of the State Drug Administration announced that the clinical trial application for Novo Nordisk's Class 1 new drug amycretin tablets was accepted.
Cinda Biotech will release preclinical data from multiple innovative pipelines at the American Association for Cancer Research (AACR) in 2024
Rockville, USA, April 8, 2024 /PRNewswire/ -- Cinda Biopharmaceuticals Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs in major diseases such as oncology, autoimmunity, metabolism, cardiovascular, ophthalmology, etc., announced today that it will announce a number of the latest preclinical data at the 2024 American Association for Cancer Research (AACR) tumor pipeline. Late-Breaking Resear
Innovent Biologics New Cancer Drug Gets NDA From Chinese Authority
Innovent Biologics (HKG:1801) said China's National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) and granted priority review designation for the combination of sintil
Hehuang Pharmaceutical (00013) and Cinda Biotech announce that the marketing application for fruquintinib (fruquintinib) combined with sintilimab (sintilimab) for the treatment of advanced endometrial cancer in China has been accepted and included in prio
Hehuang Pharmaceutical (00013) issued an announcement. Today, Hehuang Pharmaceutical (China) Co., Ltd. and Innovent Biologics, Inc. jointly announced that the new drug marketing application for patients with advanced mismatch repair (pMMR1) or non-microsatellite-highly unstable (non-MSI-H2) endometrial cancer patients using a combination of furoquintinib and cindilizumab to treat disease progression after previous systemic anti-tumor treatment and is not suitable for radical surgical treatment or radical radiotherapy (non-) has been accepted and prioritized by the China National Drug Administration.
[Hong Kong Stock Connect] Cinda Biotech (01801) was approved by the State Drug Administration to launch a new drug in combination therapy with cindilimab and fruquintinib
Jinwu Financial News | Cinda Biotech (01801) announced that China's National Drug Administration (“NMPA”) has officially accepted a new drug marketing application (“NDA”) for the combination therapy of cindilimab and furoquintinib and has granted priority review qualifications to treat patients with advanced mismatch repair (“pMMR”) or advanced mismatch repair (“non-MSI-H”) with advanced mismatch repair (“non-MSI-H”) after previous systemic antineoplastic treatment and is unsuitable for radical surgery or radical radiotherapy (“non-MSI-H”) endometrial cancer patients. The FRUSICA-1 study data supports this NDA. FRUSICA-
Cinda Biotech (01801.HK): The China Drug Administration accepted the marketing application for a new drug with cindilimab combined with fruquintinib for the treatment of advanced endometrial cancer and granted priority review
Cinda Biotech (01801.HK) announced that China's National Drug Administration (“NMPA”) has officially accepted a new drug marketing application (“NDA”) for the combination therapy of cindilimab and furoquintinib and has granted priority review qualifications to treat patients with advanced mismatch repair (“pMMR”) or advanced mismatch repair (“non-MSI-H”) with advanced mismatch repair (“non-MSI-H”) after previous systemic anti-tumor treatment and are unsuitable for radical surgical treatment or radical radiotherapy (“non-MSI-H”) endometrial cancer patients.
Shanghai Securities: A new mechanism for oral antihypertensive drugs has been approved by the FDA for marketing, and attention is being paid to the cardiovascular drug circuit
The Zhitong Finance App learned that Shanghai Securities released a research report saying that on March 19, the US FDA announced approval for the launch of Tryvio, a new molecular physical drug developed by Idorsia. Tryvio is an endothelin receptor antagonist used to treat high blood pressure that is still insufficiently controlled when combined with other antihypertensive drugs. Notably, Tryvio is the first oral antihypertensive therapy approved to work through a new treatment route in nearly 30 years. According to the “China Cardiovascular Health and Disease Report 2022”, the prevalence of cardiovascular disease in China continues to rise. The current number of patients is estimated to be 330 million.
Cinda Biotech (01801) anti-CTLA-4 monoclonal antibodi+anti-PD-1 monoclonal antibody to be included in breakthrough treatment varieties
Zhitong Finance App learned that on March 29, the China National Drug Administration Drug Evaluation Center (CDE) official website announced that Cinda Biotech (01801) IBI310 (an anti-CTLA-4 monoclonal antibody) and cindilimab (IBI308, anti-PD-1 monoclonal antibody) products are intended to be included in breakthrough treatment varieties. The indications are IBI310 combined with cindilimab for resectable high-microsatellite instability (MSI-H) or mismatch to repair genodefective (dMMR) colon cancer. According to a recent press release issued by Cinda Biotech, IBI310 in conjunction with cindilimab
[Broker Focus] Guosheng Securities maintains Cinda Biotech (01801) “buys” ratings to accelerate the company's non-tumor pipeline
Jinwu Financial News | Guosheng Securities released research reports that Cinda Biotech (01801) released 2023 results, and the company achieved total revenue of 6.206 billion yuan in 2023, an increase of 36.2% over the previous year; adjusted losses were 515 million yuan, compared to 2,462 billion yuan for the same period in 2022, a year-on-year reduction of 79.1%. According to the bank, at present, the company has commercialized 10 products, 3 products have submitted NDA, 5 products have entered phase 3/critical clinical trials, and 18 products are in early clinical trials. Non-oncology fields include metabolic & cardiovascular, endocrinology, and ophthalmology, and PCSK9 monoclonal antibodies have been approved for marketing
Bank Rating | CCB International: Raising Cinda Biotech's Target Price to HK$54.3 to Maintain “Outperform the Market” Rating
CCB International raised Cinda Biotech's target price from HK$54.2 to HK$54.3, maintaining the “outperforming the market” rating. It believes that its outlook is stable and has a good catalyst. The results for the full year and the second half of last year beat expectations. Based on stable biotechnology fundamentals, it is the bank's first choice in the healthcare and biotechnology sector in the mainland. The bank believes that its lung cancer drug Tyvyt has multiple treatment indications in the national medical insurance list, and there is no need to drastically lower the price. It believes that the company can maintain product sales growth this year, estimated at 23% year-on-year, while the driving force of other drugs will also increase, and the commercialization process will continue to advance.
Innovent Biologics Could Break Even by 2025 -- Market Talk
0810 GMT - Innovent Biologics' target of Ebitda break-even by 2025 appears achievable with effective cost-control measures, HSBC Qianhai analysts Linda Shu and Cindy Chai say in a note after the bioph
Changes in Hong Kong stocks | Cinda Biotech (01801) is now up more than 4%, and HSBC is optimistic that the company's drug commercialization progress will reach balance of payments next year
Cinda Biotech (01801) is now up more than 4%. As of press release, it is up 4.29% to HK$38.9 million, with a turnover of HK$153 million.
Southwest Securities: Cinda Biotech (01801) had a high increase in product revenue in 23, and the progress of many key products this year is worth looking forward to in ratings and maintaining purchases
In 2024, Cinda Biotech's major product, Maxidu Peptide, is expected to read the results of Phase 3 of DREAMS-1 and DREAMS-2 to support the submission of a second NDA for the treatment of T2D.
Analysis
Price Target
No Data
